Show simple item record

dc.contributor.authorYun Ooi, K
dc.contributor.authorPereira, I
dc.contributor.authorNagar, H
dc.contributor.authorSimcock, R
dc.contributor.authorKatz, MS
dc.contributor.authorParker, CC
dc.contributor.authorLawton, C
dc.contributor.authorSaeed, H
dc.date.accessioned2022-01-27T10:41:21Z
dc.date.available2022-01-27T10:41:21Z
dc.identifier.citationClinical and translational radiation oncology, 2021, 31 pp. 21 - 27en_US
dc.identifier.issn2405-6308
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4984
dc.identifier.eissn2405-6308en_US
dc.identifier.eissn2405-6308
dc.identifier.doi10.1016/j.ctro.2021.07.003en_US
dc.identifier.doi10.1016/j.ctro.2021.07.003
dc.description.abstract<h4>Background</h4>Management of prostate cancer after surgery is controversial. Past studies on adjuvant radiotherapy (aRT) for higher-risk features have had conflicting results. Through the collaborative conversations of the global radiation oncology Twitter-based journal club (#RadOnc #JC), we explored this complex topic to share recent advances, better understand what the global radiation oncology community felt was important and inspire next steps.<h4>Methods</h4>We selected the recent publication of a landmark international randomized controlled trial (RCT) comparing immediate and salvage radiotherapy for prostate cancer, RADICALS-RT, for discussion over the weekend of January 16 to 17, 2021. Coordination included open access to the article and an asynchronous portion to decrease barriers to participation, cooperation of study authors (CP, MS) who participated to share deeper insights including a live hour, and curation of related resources and tweet content through a blog post and Wakelet journal club summary.<h4>Discussion of results</h4>Our conversations created 2,370,104 impressions over 599 tweets with 51 participants spanning 11 countries and 5 continents. A quarter of the participants were from the US (13/51) followed by 10% from the UK (5/51). Clinical or Radiation Oncologists comprised 59% of active participants (16/27) with 62% (18/29) reporting giving aRT within the last 5 years. Discussion was interdisciplinary with three urologists (11%), three trainees (11%), and two physiotherapists (7%). Four months after the journal club its article Altmetric score had increased by 7% (214 to 229). Thematic analysis of tweet content suggested participants wanted clarification on definitions of adjuvant (aRT) and salvage radiotherapy (sRT) including indications, timing, and decision-making tools including guidelines; more interdisciplinary and cross-sectoral collaboration including with patients for study design including survivorship and meaningful outcomes; more effective knowledge translation including faster clinical trials; and more data including mature results of current trials, particular high-risk features (Gleason Group 4+, pT4b+, and margin-positive disease), implications of newer technologies such as PSMA-PET and genomic classifiers, and better explanations for practice pattern variations including underutilization of radiotherapy. This was further explored in the context of relevant literature.<h4>Conclusion</h4>Together, this global collaborative review on the postoperative management of prostate cancer suggested a stronger signal for the uptake of early salvage radiation treatment with careful PSA monitoring, more sensitive PSA triggers, and expected access to radiotherapy. Questions still remain on potential exceptions and barriers to use. These require better decision-making tools for all practice settings, consideration of newer technologies, more pragmatic trials, and better use of social media for knowledge translation.en_US
dc.formatElectronic-eCollectionen_US
dc.format.extent21 - 27en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleTime management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation.en_US
dc.typeJournal Article
dcterms.dateAccepted2021-07-26
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.ctro.2021.07.003en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.relation.isPartOfClinical and translational radiation oncologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume31en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorParker, Chrisen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/